Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial.

Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. J Am Coll Cardiol (2004) 1.95

Trends in utilization and complications of catheter ablation for atrial fibrillation in Medicare beneficiaries. Heart Rhythm (2009) 1.82

Precision medicine to improve use of bleeding avoidance strategies and reduce bleeding in patients undergoing percutaneous coronary intervention: prospective cohort study before and after implementation of personalized bleeding risks. BMJ (2015) 1.59

A cost-minimization analysis of the angio-seal vascular closure device following percutaneous coronary intervention. Am J Cardiol (2007) 1.14

The economic burden of complications during percutaneous coronary intervention. Qual Saf Health Care (2007) 0.90

Clinical and economic studies of eptifibatide in coronary stenting. Ther Clin Risk Manag (2014) 0.81

Antiplatelet therapy in patients undergoing percutaneous coronary intervention: economic considerations. Pharmacoeconomics (2013) 0.81

An overview of PCI in the very elderly. J Geriatr Cardiol (2015) 0.79

The Role of Glycoprotein IIb/IIIa Inhibitors- A Promise Not Kept? Curr Cardiol Rev (2008) 0.77

Direct thrombin inhibitors in cardiovascular disease. Nat Rev Cardiol (2012) 0.77

Bivalirudin in percutaneous coronary intervention. Vasc Health Risk Manag (2006) 0.76

Angiographic and clinical outcomes of bivalirudin versus heparin in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Can J Cardiol (2006) 0.75

Economic impact of new interventional therapies: are we asking the right questions? J Am Coll Cardiol (2004) 0.75

PCI with bivalirudin and provisional GP IIb/IIIa inhibition is more cost-effective than heparin plus routine GP IIb/IIIa inhibition. Commentary. Evid Based Cardiovasc Med (2005) 0.75

The comparative efficacy of bivalirudin is markedly attenuated by use of radial access: insights from Blue Cross Blue Shield of Michigan Cardiovascular Consortium. Eur Heart J (2015) 0.75

Adjunct bivalirudin dosing protocol for neuro-endovascular procedures. J Vasc Interv Neurol (2008) 0.75

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25

Assessing the impact of population stratification on genetic association studies. Nat Genet (2004) 16.28

Human genetic variation and its contribution to complex traits. Nat Rev Genet (2009) 12.11

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA (2002) 11.06

ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol (2007) 10.19

Evaluation of next generation sequencing platforms for population targeted sequencing studies. Genome Biol (2009) 9.59

Effect of direct-to-consumer genomewide profiling to assess disease risk. N Engl J Med (2011) 6.90

Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet (2003) 6.85

Common vs. rare allele hypotheses for complex diseases. Curr Opin Genet Dev (2009) 6.85

Prevalence of conventional risk factors in patients with coronary heart disease. JAMA (2003) 6.84

ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation (2007) 6.78

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA (2008) 6.55

Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA (2011) 6.39

Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA (2004) 6.28

9p21 DNA variants associated with coronary artery disease impair interferon-γ signalling response. Nature (2011) 6.25

Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med (2003) 5.89

A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol (2003) 5.51

Bivalirudin for patients with acute coronary syndromes. N Engl J Med (2006) 5.49

Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet (2003) 5.34

The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet (2004) 5.31

Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA (2004) 5.11

Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet (2002) 5.04

Microdroplet-based PCR enrichment for large-scale targeted sequencing. Nat Biotechnol (2009) 4.80

Can mobile health technologies transform health care? JAMA (2013) 4.75

Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA (2003) 4.74

Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med (2003) 4.72

A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet (2005) 4.45

N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation (2003) 4.31

Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med (2007) 4.30

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA (2005) 4.23

Pathway analysis of seven common diseases assessed by genome-wide association. Genomics (2008) 4.11

Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet (2010) 3.97

Lymphocyte recruitment into the aortic wall before and during development of atherosclerosis is partially L-selectin dependent. J Exp Med (2006) 3.65

Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA (2008) 3.64

Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation (2003) 3.38

2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J Am Coll Cardiol (2011) 3.37

Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science (2003) 3.34

Intravenous platelet blockade with cangrelor during PCI. N Engl J Med (2009) 3.31

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med (2011) 3.20

Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. Ann Intern Med (2010) 3.17

Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA (2008) 3.09

Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA (2007) 3.07

Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol (2005) 3.05

Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. N Engl J Med (2002) 3.01

Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation (2011) 2.98

Characterization of circulating endothelial cells in acute myocardial infarction. Sci Transl Med (2012) 2.91

Arthritis medicines and cardiovascular events--"house of coxibs". JAMA (2004) 2.89

2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2012) 2.88

Drug-eluting stents: an early systematic review to inform policy. Eur Heart J (2004) 2.88

Accurate detection and genotyping of SNPs utilizing population sequencing data. Genome Res (2010) 2.84

Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J (2005) 2.80

2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2011) 2.72

Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation (2002) 2.69

Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet (2007) 2.67

Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet (2009) 2.62

Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med (2008) 2.61

Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol (2005) 2.59

Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol (2007) 2.56

Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 2.56

Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features. Circulation (2004) 2.54

2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2012) 2.52

Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med (2009) 2.52

Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 2.50

Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trial. J Am Coll Cardiol (2007) 2.47

Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation (2009) 2.47

International differences in evolution of early discharge after acute myocardial infarction. Lancet (2004) 2.47

A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol (2007) 2.47

2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2011) 2.45

The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? Per Med (2011) 2.43

Molecular imaging of inflammation in atherosclerosis with targeted ultrasound detection of vascular cell adhesion molecule-1. Circulation (2007) 2.40

2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol (2011) 2.37

Premature myocardial infarction novel susceptibility locus on chromosome 1P34-36 identified by genomewide linkage analysis. Am J Hum Genet (2004) 2.36

Enrichment of sequencing targets from the human genome by solution hybridization. Genome Biol (2009) 2.32

An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J (2007) 2.31

Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial. Circulation (2004) 2.28

Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation (2010) 2.27

Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA (2005) 2.26

The importance of phase information for human genomics. Nat Rev Genet (2011) 2.25

Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke (2004) 2.24

Consumer perceptions of direct-to-consumer personalized genomic risk assessments. Genet Med (2010) 2.23

The case for routine genotyping in dual-antiplatelet therapy. J Am Coll Cardiol (2010) 2.19

Sex differences in mortality following acute coronary syndromes. JAMA (2009) 2.17

Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET). J Am Coll Cardiol (2003) 2.17

Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol (2007) 2.14

Single injection of P-selectin or P-selectin glycoprotein ligand-1 monoclonal antibody blocks neointima formation after arterial injury in apolipoprotein E-deficient mice. Circulation (2003) 2.11

The subendothelial extracellular matrix modulates NF-kappaB activation by flow: a potential role in atherosclerosis. J Cell Biol (2005) 2.07

Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov (2003) 2.06

Cost-effectiveness of distal embolic protection for patients undergoing percutaneous intervention of saphenous vein bypass grafts: results from the SAFER trial. J Am Coll Cardiol (2004) 2.05

Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation (2008) 2.05

The genetics of health. Nat Genet (2006) 2.04

Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs. Am J Med (2006) 2.02

Enhanced prediction of mortality after percutaneous coronary intervention by consideration of general and neurological indicators. JACC Cardiovasc Interv (2011) 2.01

Towards precise classification of cancers based on robust gene functional expression profiles. BMC Bioinformatics (2005) 2.01

A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg (2006) 2.00